- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:30 | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14:26 | OSR Health, Inc.: OSR Health Provides Shareholder Update Following Nasdaq Panel Decision | 218 | ACCESS Newswire | Company evaluating options to regain compliance; further update expected by November 6, 2026; $15 million VXM01 funding mechanism remains in place; committed to continuing Shareholder Loyalty Program... ► Artikel lesen | |
| 16.10. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.08. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc. | 714 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report... ► Artikel lesen | |
| OSR HEALTH Aktie jetzt für 0€ handeln | |||||
| 21.08. | OSR Health, Inc.: OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission | 648 | ACCESS Newswire | The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc.... ► Artikel lesen | |
| 19.08. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.08. | OSR Health faces Nasdaq delisting over bid-price rule | 1 | Seeking Alpha | ||
| 19.08. | OSR Health droht NASDAQ-Delisting nach Verstoß gegen Mindestkurs-Anforderung | 1 | Investing.com Deutsch | ||
| 19.08. | Nasdaq to delist OSR Health after bid price compliance failure | 1 | Investing.com | ||
| 19.08. | OSR Health, Inc.: OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal | 1.510 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination")... ► Artikel lesen | |
| 19.08. | OSR Health, Inc.: OSR Health Sees Global Shareholder Momentum at Critical Inflection Point | 768 | ACCESS Newswire | Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health... ► Artikel lesen | |
| 14.08. | OSR Health, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | Drohendes NASDAQ-Delisting: OSR Health verweist auf Lizenzgespräche | 19 | Investing.com Deutsch | ||
| 11.08. | OSR Health, Inc.: OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development | 793 | ACCESS Newswire | Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today... ► Artikel lesen | |
| 10.08. | OSR Health: Aktionäre bestätigen Vorstand und genehmigen wichtige Anträge auf Hauptversammlung | 7 | Investing.com Deutsch | ||
| 07.08. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | OSR Health, Inc.: OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program | 595 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning... ► Artikel lesen | |
| 03.08. | OSR Health subsidiary completes glioblastoma vaccine analysis | 4 | Investing.com |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,634 | +19,29 % | Here's Why You Should Hold PacBio Stock in Your Portfolio for Now | ||
| CYTOMX THERAPEUTICS | 2,069 | -1,43 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 5,738 | +5,63 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| CORMEDIX | 7,256 | +0,92 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,883 | -3,09 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia | BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| REPLIMUNE | 12,760 | +8,92 % | Replimune Group Q2 2027 Earnings Call Transcript | ||
| VALERIO THERAPEUTICS | 0,420 | +6,33 % | Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic | Shareholder approval and settlement and delivery of the capital increases related to the Acquisition
The Acquisition marks a major milestone in Valerio's strategy to build a leading integrated... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,606 | 0,00 % | Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) | SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 23,160 | -0,09 % | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics aktiviert UC Davis als klinisches Studienzentrum für CER-1236-Studie | ||
| QIAGEN | 45,130 | 0,00 % | Qiagen sorgt für Wirbel: 10,8-Milliarden-Deal begeistert Anleger | Der Diagnostikspezialist Qiagen steht vor einer milliardenschweren Übernahme und sorgt damit für Begeisterung an der Börse. Der schwedische Finanzinvestor EQT bietet 46,50 Euro je Aktie und bewertet... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,675 | -17,67 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| BEAM THERAPEUTICS | 26,940 | +8,15 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen |
Das Unternehmen OSR HEALTH INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,003 (-2,75 %) liegt der Kurs bei 0,113 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HEALTH INC finden Sie auf Wallstreet Online.